The DOI matches its Crossref record.
European Organization for Research and Treatment of Cancer
Open accessAbstract
Primary cutaneous B-cell lymphomas (CBCL) represent approximately 20-25% of all primary cutaneous lymphomas. With the advent of the World Health Organization-European Organization for Research and Treatment of Cancer (EORTC) consensus classification for cutaneous lymphomas in 2005, uniform terminology and classification for this rare group of neoplasms was introduced. However, staging procedures and treatment strategies still vary between different cutaneous lymphoma centres, which may be due to the fact that consensus recommendations for the management of CBCL have never been published. Based on an extensive literature search and discussions within the EORTC Cutaneous Lymphoma Group and the International Society for Cutaneous Lymphomas, the present report aims to provide uniform recommendations for the management of the three main groups of CBCL. Since no systematic reviews or (randomized) controlled trials were available, these recommendations are mainly based on retrospective studies and small cohort studies. Despite these limitations, there was consensus among the members of the multidisciplinary expert panel that these recommendations reflect the state of the art management as currently practised in major cutaneous lymphoma centres. They may therefore contribute to uniform staging and treatment and form the basis for future clinical trials in patients with a CBCL. of (11%) with a (FCL) first presenting in the as compared to two of 82 patients with a marginal zone lymphoma (MZL) In nine of these 22 the only evidence of extracutaneous disease. The 5-year overall and disease-specific survivals of these nine patients were 44% and 63%, respectively, compared to 84% and 95% in 157 patients without extracutaneous disease. indicate that bone marrow examination should be considered as an essential part of staging procedures in patients with a FCL first presenting in the skin and that, from a clinical point of view, bone marrow examination appears to have limited value in
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Evaluating patient-based outcome measures for use in clinical trials.
Fitzpatrick, Davey, Buxton, & Jones (1998) · Health Technology Assessment · doi:10.3310/hta2140 · Cited by 1,715
Groenvold, M., Petersen, M. A., Aaronson, N. K., Arraras, J. I., Blazeby, J. M., Bottomley, A., Fayers, P. M., de Graeff, A., Hammerlid, E., Kaasa, S., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.06.022 · Cited by 678
Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study
Ortner, M. E. J., Caca, K., Berr, F., Liebetruth, J., Mansmann, U., Huster, D., Voderholzer, W., Schachschal, G., Mössner, J., & Lochs, H. (2003) · Gastroenterology · doi:10.1016/j.gastro.2003.07.015 · Cited by 608
Coleman, R. E., Major, P., Lipton, A., Brown, J. E., Lee, K.-A., Smith, M., Saad, F., Zheng, M., Hei, Y. J., Seaman, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.091 · Cited by 533
Metadata
- Authors
- National Cancer Institute
- Venue
- Definitions
- Publisher
- Qeios
- Published
- 2020-02-02
- Volume
- 30
- Issue
- 3
- Pages
- 169-169
- OpenAlex
- W2401722066
- Cited by
- 756
- References
- 0
- Type
- reference entry
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: European Organization for Research and Treatment of Cancer. https://app.cochat.ai/papers/10.32388/ykqg4k
- The paper
- National Cancer Institute. (2020). European Organization for Research and Treatment of Cancer. Definitions. https://doi.org/10.32388/ykqg4k
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
